JP2013147480A5 - - Google Patents

Download PDF

Info

Publication number
JP2013147480A5
JP2013147480A5 JP2012011342A JP2012011342A JP2013147480A5 JP 2013147480 A5 JP2013147480 A5 JP 2013147480A5 JP 2012011342 A JP2012011342 A JP 2012011342A JP 2012011342 A JP2012011342 A JP 2012011342A JP 2013147480 A5 JP2013147480 A5 JP 2013147480A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glucose
composition according
agent
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012011342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013147480A (ja
JP5456802B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2012011342A external-priority patent/JP5456802B2/ja
Priority to JP2012011342A priority Critical patent/JP5456802B2/ja
Priority to HK15105077.8A priority patent/HK1204556B/en
Priority to EP13740840.7A priority patent/EP2808025B1/en
Priority to KR1020147020143A priority patent/KR101514257B1/ko
Priority to PCT/JP2013/051159 priority patent/WO2013111729A1/ja
Priority to TW102102452A priority patent/TWI468184B/zh
Publication of JP2013147480A publication Critical patent/JP2013147480A/ja
Publication of JP2013147480A5 publication Critical patent/JP2013147480A5/ja
Publication of JP5456802B2 publication Critical patent/JP5456802B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012011342A 2012-01-23 2012-01-23 細胞遊走促進剤及び創傷治療用の経皮吸収剤 Active JP5456802B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2012011342A JP5456802B2 (ja) 2012-01-23 2012-01-23 細胞遊走促進剤及び創傷治療用の経皮吸収剤
PCT/JP2013/051159 WO2013111729A1 (ja) 2012-01-23 2013-01-22 医薬組成物及びこれを用いた薬用化粧品
EP13740840.7A EP2808025B1 (en) 2012-01-23 2013-01-22 Pharmaceutical composition and quasi-drug cosmetic using same
KR1020147020143A KR101514257B1 (ko) 2012-01-23 2013-01-22 의약 조성물 및 이를 이용한 약용 화장품
HK15105077.8A HK1204556B (en) 2012-01-23 2013-01-22 Pharmaceutical composition and quasi-drug cosmetic using same
TW102102452A TWI468184B (zh) 2012-01-23 2013-01-23 藥學組成物及使用其之藥用化妝品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012011342A JP5456802B2 (ja) 2012-01-23 2012-01-23 細胞遊走促進剤及び創傷治療用の経皮吸収剤

Publications (3)

Publication Number Publication Date
JP2013147480A JP2013147480A (ja) 2013-08-01
JP2013147480A5 true JP2013147480A5 (https=) 2013-09-26
JP5456802B2 JP5456802B2 (ja) 2014-04-02

Family

ID=48873449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012011342A Active JP5456802B2 (ja) 2012-01-23 2012-01-23 細胞遊走促進剤及び創傷治療用の経皮吸収剤

Country Status (5)

Country Link
EP (1) EP2808025B1 (https=)
JP (1) JP5456802B2 (https=)
KR (1) KR101514257B1 (https=)
TW (1) TWI468184B (https=)
WO (1) WO2013111729A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6313118B2 (ja) * 2014-05-16 2018-04-18 株式会社Cac ＩｇＥ抑制剤
JP6584494B2 (ja) * 2014-09-12 2019-10-02 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ メラニン産生細胞のｈｍｇｂ１活性化を阻害する方法、そのような阻害に好適な薬剤を特定する方法
JP2018172328A (ja) 2017-03-31 2018-11-08 株式会社Cac 皮膚バリア増強剤、医薬組成物、薬用化粧品、及び美容方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138432A (ja) * 1985-12-12 1987-06-22 Shionogi & Co Ltd 抗炎症ステロイドを含有する安定な錠剤
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
CN1116095A (zh) * 1994-08-03 1996-02-07 鞍山钢铁公司 一种用于治疗烧伤的胶浆剂
JP2920611B2 (ja) * 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
JP2005281315A (ja) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc 水性薬理組成物
SE9704833D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New formulation
US7897161B2 (en) * 2002-06-03 2011-03-01 Cac Corporation External medicine for treating dermatitis
WO2004082590A2 (en) * 2003-02-17 2004-09-30 Sun Pharmaceutical Industries Limited A low dose corticosteroid composition
CN1255184C (zh) * 2004-03-22 2006-05-10 中国人民解放军第四军医大学 葡萄糖－胰岛素－钾极化液在制备外敷治疗创伤、烧伤的药物中的应用
JP4854194B2 (ja) * 2004-07-05 2012-01-18 株式会社ファンケル ラメラ構造再生剤及び皮膚外用剤
WO2006027787A1 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
JP2007182384A (ja) 2004-09-22 2007-07-19 New Industry Research Organization 抗炎症治療薬
AU2006244873A1 (en) * 2005-05-13 2006-11-16 Netech Inc. Medical composition for promotion of skin regeneration
JP2008273919A (ja) 2007-05-07 2008-11-13 Lilac:Kk 組織・細胞障害のための予防・修復剤
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Similar Documents

Publication Publication Date Title
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
HUE048859T2 (hu) Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
JP2009256391A5 (https=)
CL2014001437A1 (es) Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades.
JP2014530840A5 (https=)
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
PH12015500746A1 (en) Benzamides
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
ZA201406403B (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
JP2013533867A5 (https=)
EP2533763C0 (de) Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide
JP2013147480A5 (https=)